Hamilton Capital LLC Grows Stock Position in AbbVie Inc. $ABBV

Key Points

• Hamilton Capital increased its AbbVie position by 870.4% in the second quarter, bringing its holdings to 47,315 shares valued at approximately $11.9 million. Institutional investors collectively own 70.23% of the company.
• AbbVie reported better-than-expected quarterly results, with earnings of $3.65 per share and revenue of $16.99 billion, up 10.2% year over year. The company issued third-quarter EPS guidance of $3.84 to $3.88.
• Analysts maintain a favorable outlook, with a consensus rating of “Moderate Buy” and an average price target of $275.95, compared with the stock’s reported price of $256.27. AbbVie also pays a quarterly dividend of $1.73 per share, yielding about 2.7% annually.

Hamilton Capital LLC raised its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 870.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,315 shares of the company's stock after acquiring an additional 42,439 shares during the quarter. AbbVie accounts for about 0.6% of Hamilton Capital LLC's investment portfolio, making the stock its 11th largest holding. Hamilton Capital LLC's holdings in AbbVie were worth $11,906,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new stake in AbbVie during the 4th quarter valued at $5,865,055,000. Corient Private Wealth LP acquired a new position in AbbVie in the 2nd quarter worth $559,736,000. Legal & General Group Plc acquired a new position in AbbVie in the 2nd quarter worth $2,905,952,000. Wellington Management Group LLP boosted its position in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock valued at $2,439,714,000 after buying an additional 8,646,424 shares during the last quarter. Finally, Capital World Investors grew its stake in shares of AbbVie by 106.3% during the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company's stock valued at $2,986,777,000 after acquiring an additional 6,736,161 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of analyst reports. Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 5th. Cantor Fitzgerald increased their price target on AbbVie from $265.00 to $285.00 and gave the company an "overweight" rating in a report on Monday, August 3rd. JPMorgan Chase & Co. lifted their price objective on AbbVie from $260.00 to $280.00 and gave the stock an "overweight" rating in a report on Thursday, July 9th. Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a research report on Wednesday, August 5th. Finally, Citigroup increased their target price on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research note on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $275.95.

AbbVie Price Performance

AbbVie stock opened at $256.27 on Friday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The company has a fifty day moving average price of $254.66 and a two-hundred day moving average price of $230.06. The company has a market cap of $452.78 billion, a PE ratio of 72.39, a P/E/G ratio of 1.16 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. During the same period in the prior year, the company earned $2.97 earnings per share. The firm's revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie's dividend payout ratio is 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source